Next 10 |
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in H...
2024-05-07 13:24:31 ET More on Design Therapeutics Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design T...
2024-05-07 12:46:58 ET More on Mid-day movers & stocks. Pineapple Energy Inc. (PEGY) Q4 2023 Earnings Call Transcript Financial information for Integrated Media Technology Financial information for Mmtec Seeking Alpha’s Quant Rating on Pineapple En...
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conf...
2024-03-19 20:44:02 ET Design Therapeutics, Inc. (DSGN) Q4 2023 Results Conference Call March 19, 2024 4:30 PM ET Company Participants Sean Jeffries - COO Pratik Shah - Chairman, CEO Conference Call Participants Joseph Schwartz - Leerink Partners Laur...
2024-03-19 16:07:28 ET More on Design Therapeutics Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design Therapeutics Read the full article on Seeking Alpha For fur...
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) wit...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30...
News, Short Squeeze, Breakout and More Instantly...
Design Therapeutics Inc. Company Name:
DSGN Stock Symbol:
NASDAQ Market:
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in H...
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conf...
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern arou...